Menopause Care Launch: Recent chatter on X about Hims & Hers Health (HIMS) has been fueled by the company’s new menopause and perimenopause care program. Many see this as a bold step into a critical area of women’s health, sparking excitement over potential market growth. The move is viewed as a strategic play to address unmet healthcare needs.
Telehealth Innovation: Beyond the new program, discussions on X often highlight HIMS’s disruptive telehealth model, especially its cash-pay approach that sidesteps traditional insurance. There’s curiosity about whether this model can scale globally, though some express caution over competitive pressures and recent stock volatility. The conversation remains lively with speculation on long-term potential.
Weight-Loss Drug Expansion: Another hot topic on X is HIMS’s push into the weight-loss drug market ahead of its Q3 earnings. Posts reflect intrigue over how this could impact the stock, with some viewing it as a significant growth driver. The buzz keeps investors engaged as results loom.
Note: This discussion summary was generated from an AI condensation of post data.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 87 times in the past 6 months. Of those trades, 0 have been purchases and 87 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 39 sales selling 1,668,525 shares for an estimated $86,780,236.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 13 sales selling 369,364 shares for an estimated $20,394,289.
- MICHAEL CHI (Chief Commercial Officer) has made 0 purchases and 13 sales selling 91,401 shares for an estimated $5,410,838.
- PATRICK HARRISON CARROLL (Chief Medical Officer) has made 0 purchases and 2 sales selling 70,021 shares for an estimated $3,720,938.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 13 sales selling 37,898 shares for an estimated $2,039,953.
- MELISSA BAIRD (Chief Operating Officer) has made 0 purchases and 4 sales selling 33,333 shares for an estimated $1,867,376.
- IRENE BECKLUND (PAO) has made 0 purchases and 3 sales selling 21,966 shares for an estimated $1,203,032.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Hims & Hers Health Congressional Stock Trading
Members of Congress have traded $HIMS stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Hims & Hers Health Hedge Fund Activity
We have seen 306 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 221 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 18,559,302 shares (+inf%) to their portfolio in Q2 2025, for an estimated $925,181,204
- D. E. SHAW & CO., INC. removed 4,143,604 shares (-68.7%) from their portfolio in Q2 2025, for an estimated $206,558,659
- INVESCO LTD. added 2,128,587 shares (+502.2%) to their portfolio in Q2 2025, for an estimated $106,110,061
- CONTRARIUS GROUP HOLDINGS LTD removed 1,749,968 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $87,235,904
- CLEAR STREET LLC added 1,676,667 shares (+inf%) to their portfolio in Q2 2025, for an estimated $83,581,849
- NORGES BANK added 1,574,009 shares (+inf%) to their portfolio in Q2 2025, for an estimated $78,464,348
- BANK OF MONTREAL /CAN/ added 1,515,809 shares (+5701.5%) to their portfolio in Q2 2025, for an estimated $75,563,078
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Hims & Hers Health Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/12/2025
To track analyst ratings and price targets for Hims & Hers Health, check out Quiver Quantitative's $HIMS forecast page.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 4 analysts offer price targets for $HIMS in the last 6 months, with a median target of $52.5.
Here are some recent targets:
- Maria Ripps from Canaccord Genuity set a target price of $68.0 on 09/12/2025
- Jailendra Singh from Truist Securities set a target price of $37.0 on 08/18/2025
- Craig Hettenbach from Morgan Stanley set a target price of $40.0 on 06/11/2025
- Ryan MacDonald from Needham set a target price of $65.0 on 06/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
